Clinical Trial Update: A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Biotroy Therapeutics is conducting a Phase 1/2 study of BT02 for relapsed or refractory hematologic malignancies, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma

Drugs mentioned

• BT02

Snippet

Sponsor: Biotroy Therapeutics | Conditions: Relapsed or Refractory Hematologic Malignancies, Leukemia | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING